In the present study, patients with higher TNR have better survival, although this did not reach statistical significance due to the relatively small sample size and limited time of follow‐up (Figure S2 ).
← all excerpts
Camrelizumab in combination with doxorubicin, cisplatin, ifosfamide, and methotrexate in neoadjuvant treatment of resectable osteosarcoma: A prospective, single-arm, exploratory phase II trial.
1
—
—